The benefits are in fact clear regardless
and potentially early insight into health system impact, e.g., cost offsets, or trends in population-level outcomes related to obesity, e.g., prevalence, morbidity or mortality
Access to all 50 states without insurance requirements or membership fees means consistent supply regardless of insurance coverage gaps
There are specific differences that affect how theyre prescribed, used, and covered by insurance
Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
